September 21, 2009

7 abstracts with contributors from the Knight Cancer Institute/OHSU Department of Radiation Medicine were submitted to the GI Cancer Symposium, to be held in Orlando in January 2010.

Abstracts submitted:

Gunderson LL, Moughan J, Ajani JA, Pedersen J, Benson A III, Thomas CR Jr., Mayer R, Haddock M, Rich T, Willett C: Anal carcinoma:  Impact of TN category of disease on survival and disease relapse in US GI Intergroup RTOG 98-11 phase III trial. Proceedings of the 2010 Gastrointestinal Cancers Symposium, Orlando, Jan 15-17. 2010 (Oral presentation)

Thomas CR Jr., Goldman BH, Benedetti JK, Lenz HJ, Beeker T, Abbruzzese JL, Blanke CD: Cetuximab plus cisplatin, irinotecan and thoracic radiotherapy (TRT) as definitive treatment for locally advanced, unresectable esophageal cancer (EC): a SWOG (S0414) phase II trial. Proceedings of the 2010 Gastrointestinal Cancers Symposium, Orlando, Jan 15-17. 2010 (Poster presentation)

Walker GV, McDonald TL, Schwartz J, Naugler W, Kolbeck K, Kaufman J, Billingsley KG, Orloff S, Fuss M : Outcomes of stereotactic body radiation therapy (SBRT) and hypofractionated radiation therapy (HFxRT) for hepatocellular carcinoma (HCC). Proceedings of the 2010 Gastrointestinal Cancers Symposium, Orlando, Jan 15-17. 2010 (Poster presentation)

Walker GV, Fuller CD, Thomas CR Jr, Wang SJ: A cost analysis of mitomycin- vs. cisplatin-based definitive chemoradiotherapy for anal cancer. Proceedings of the 2010 Gastrointestinal Cancers Symposium, Orlando, Jan 15-17. 2010 (Poster presentation)

Wang SJ, Walker GV, Kalpathy-Cramer J, Kim JS, Fuller CD, Thomas CR Jr: A regression model decision aid for determining the benefit of adjuvant chemoradiotherapy for gallbladder cancer. Proceedings of the 2010 Gastrointestinal Cancers Symposium, Orlando, Jan 15-17. 2010 (Poster presentation)

Fuller CD, Nijkamp J, Rasch CRN, Kachnic LA, Okunieff P, Wang SJ, Marshall DT, Katz AW, Smith BD, Thomas CR Jr.: Impact of site-specific consensus rectal target volume atlas implementation in the cooperative group setting:  Preliminary results from a prospective randomized double-blind pilot study. Proceedings of the 2010 Gastrointestinal Cancers Symposium, Orlando, Jan 15-17. 2010 (Poster presentation)

Jenson P, McDonald TL, Thomas CR Jr.: Quality-of-life (QOL) assessment in esophageal cancer:  the Knight Cancer Institute experience. Proceedings of the 2010 Gastrointestinal Cancers Symposium, Orlando, Jan 15-17. 2010 (Poster presentation)